TCGA-PE-A5DE-01A-11R-A27Q-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 88
- os_event
- false
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.894 |
| 2 | SRR6013477 | — | cohortMD2 | 0.892 |
| 3 | SRR8613709 | — | A | 0.880 |
| 4 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.868 |
| 5 | SRR2779183 | — | — | 0.867 |
| 6 | AUR-AD9F-TTM2-A-1-1-R-A542-39 | — | D | 0.859 |
| 7 | TCGA-BH-A0B6-01A-11R-A19W-07 | — | D | 0.857 |
| 8 | TCGA-AC-A2FE-01A-11R-A19W-07 | — | A | 0.853 |
| 9 | BS_699TN5RN | Ganglioglioma | — | 0.852 |
| 10 | TCGA-LD-A9QF-01A-32R-A41B-07 | — | D | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |